Global Biologics CDMO Market Outlook, InDepth Analysis & Forecast to 2032バイオ医薬品CDMOの世界市場 2026-2032年 The global Biologics CDMO market is projected to grow from US$ 98436 million in 2025 to US$ 178798 million by 2032, at a CAGR of 8.9% (2026-2032), driven by critical product segments and diverse en... もっと見る
図表リストList of TablesTable 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Biologics CDMO Revenue by Region (US$ Million), 2021-2026 Table 7. Global Biologics CDMO Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Biologics CDMO Revenue by Players (US$ Million), 2021-2026 Table 10. Global Biologics CDMO Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics CDMO Revenue, 2025 Table 13. Global Biologics CDMO Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Biologics CDMO Companies Headquarters Table 15. Global Biologics CDMO Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Biologics CDMO Revenue by Type (US$ Million), 2021-2026 Table 19. Global Biologics CDMO Revenue by Type (US$ Million), 2027-2032 Table 20. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2021-2026 Table 21. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2027-2032 Table 22. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2021-2026 Table 23. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Biologics CDMO Revenue by Application (US$ Million), 2021-2026 Table 26. Global Biologics CDMO Revenue by Application (US$ Million), 2027-2032 Table 27. Biologics CDMO High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Biologics CDMO Growth Accelerators and Market Barriers Table 31. North America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Biologics CDMO Growth Accelerators and Market Barriers Table 33. Europe Biologics CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Biologics CDMO Growth Accelerators and Market Barriers Table 35. Asia-Pacific Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Biologics CDMO Investment Opportunities and Key Challenges Table 37. Central and South America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Biologics CDMO Investment Opportunities and Key Challenges Table 39. Middle East and Africa Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Lonza Group AG Corporation Information Table 41. Lonza Group AG Description and Major Businesses Table 42. Lonza Group AG Product Features and Attributes Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Group AG Revenue Proportion by Product in 2025 Table 45. Lonza Group AG Revenue Proportion by Application in 2025 Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025 Table 47. Lonza Group AG Biologics CDMO SWOT Analysis Table 48. Lonza Group AG Recent Developments Table 49. Samsung Biologics Co., Ltd. Corporation Information Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025 Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025 Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025 Table 56. Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis Table 57. Samsung Biologics Co., Ltd. Recent Developments Table 58. WuXi Biologics (Cayman) Inc. Corporation Information Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025 Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025 Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025 Table 65. WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis Table 66. WuXi Biologics (Cayman) Inc. Recent Developments Table 67. FUJIFILM Holdings Corporation Corporation Information Table 68. FUJIFILM Holdings Corporation Description and Major Businesses Table 69. FUJIFILM Holdings Corporation Product Features and Attributes Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025 Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025 Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025 Table 74. FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis Table 75. FUJIFILM Holdings Corporation Recent Developments Table 76. AGC Inc. Corporation Information Table 77. AGC Inc. Description and Major Businesses Table 78. AGC Inc. Product Features and Attributes Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AGC Inc. Revenue Proportion by Product in 2025 Table 81. AGC Inc. Revenue Proportion by Application in 2025 Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025 Table 83. AGC Inc. Biologics CDMO SWOT Analysis Table 84. AGC Inc. Recent Developments Table 85. Boehringer Ingelheim International GmbH Corporation Information Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim International GmbH Recent Developments Table 90. Thermo Fisher Scientific Inc. Corporation Information Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Thermo Fisher Scientific Inc. Recent Developments Table 95. Novo Holdings A/S Corporation Information Table 96. Novo Holdings A/S Description and Major Businesses Table 97. Novo Holdings A/S Product Features and Attributes Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novo Holdings A/S Recent Developments Table 100. Rentschler Biopharma SE Corporation Information Table 101. Rentschler Biopharma SE Description and Major Businesses Table 102. Rentschler Biopharma SE Product Features and Attributes Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Rentschler Biopharma SE Recent Developments Table 105. KBI Biopharma, Inc. Corporation Information Table 106. KBI Biopharma, Inc. Description and Major Businesses Table 107. KBI Biopharma, Inc. Product Features and Attributes Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. KBI Biopharma, Inc. Recent Developments Table 110. Ajinomoto Co., Inc. Corporation Information Table 111. Ajinomoto Co., Inc. Description and Major Businesses Table 112. Ajinomoto Co., Inc. Product Features and Attributes Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ajinomoto Co., Inc. Recent Developments Table 115. LOTTE BIOLOGICS Corporation Information Table 116. LOTTE BIOLOGICS Description and Major Businesses Table 117. LOTTE BIOLOGICS Product Features and Attributes Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. LOTTE BIOLOGICS Recent Developments Table 120. Polpharma Biologics Corporation Information Table 121. Polpharma Biologics Description and Major Businesses Table 122. Polpharma Biologics Product Features and Attributes Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Polpharma Biologics Recent Developments Table 125. EirGenix, Inc. Corporation Information Table 126. EirGenix, Inc. Description and Major Businesses Table 127. EirGenix, Inc. Product Features and Attributes Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. EirGenix, Inc. Recent Developments Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments Table 135. Simtra BioPharma Solutions Corporation Information Table 136. Simtra BioPharma Solutions Description and Major Businesses Table 137. Simtra BioPharma Solutions Product Features and Attributes Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Simtra BioPharma Solutions Recent Developments Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments Table 145. Piramal Pharma Limited Corporation Information Table 146. Piramal Pharma Limited Description and Major Businesses Table 147. Piramal Pharma Limited Product Features and Attributes Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Piramal Pharma Limited Recent Developments Table 150. AbbVie Inc. Corporation Information Table 151. AbbVie Inc. Description and Major Businesses Table 152. AbbVie Inc. Product Features and Attributes Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. AbbVie Inc. Recent Developments Table 155. Emergent BioSolutions Inc. Corporation Information Table 156. Emergent BioSolutions Inc. Description and Major Businesses Table 157. Emergent BioSolutions Inc. Product Features and Attributes Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Emergent BioSolutions Inc. Recent Developments Table 160. SK pharmteco Corporation Information Table 161. SK pharmteco Description and Major Businesses Table 162. SK pharmteco Product Features and Attributes Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. SK pharmteco Recent Developments Table 165. Oxford Biomedica plc Corporation Information Table 166. Oxford Biomedica plc Description and Major Businesses Table 167. Oxford Biomedica plc Product Features and Attributes Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Oxford Biomedica plc Recent Developments Table 170. WuXi XDC Cayman Inc. Corporation Information Table 171. WuXi XDC Cayman Inc. Description and Major Businesses Table 172. WuXi XDC Cayman Inc. Product Features and Attributes Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. WuXi XDC Cayman Inc. Recent Developments Table 175. Porton Pharma Solutions Ltd. Corporation Information Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. Porton Pharma Solutions Ltd. Recent Developments Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments Table 185. BioVectra Inc. Corporation Information Table 186. BioVectra Inc. Description and Major Businesses Table 187. BioVectra Inc. Product Features and Attributes Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. BioVectra Inc. Recent Developments Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments Table 195. Recipharm AB Corporation Information Table 196. Recipharm AB Description and Major Businesses Table 197. Recipharm AB Product Features and Attributes Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026) Table 199. Recipharm AB Recent Developments Table 200. Minaris Regenerative Medicine Corporation Information Table 201. Minaris Regenerative Medicine Description and Major Businesses Table 202. Minaris Regenerative Medicine Product Features and Attributes Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 204. Minaris Regenerative Medicine Recent Developments Table 205. Cellipont Bioservices Corporation Information Table 206. Cellipont Bioservices Description and Major Businesses Table 207. Cellipont Bioservices Product Features and Attributes Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026) Table 209. Cellipont Bioservices Recent Developments Table 210. Andelyn Biosciences Corporation Information Table 211. Andelyn Biosciences Description and Major Businesses Table 212. Andelyn Biosciences Product Features and Attributes Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 214. Andelyn Biosciences Recent Developments Table 215. Danaher Corporation Corporation Information Table 216. Danaher Corporation Description and Major Businesses Table 217. Danaher Corporation Product Features and Attributes Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 219. Danaher Corporation Recent Developments Table 220. BioCina Corporation Information Table 221. BioCina Description and Major Businesses Table 222. BioCina Product Features and Attributes Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026) Table 224. BioCina Recent Developments Table 225. Syngene International Limited Corporation Information Table 226. Syngene International Limited Description and Major Businesses Table 227. Syngene International Limited Product Features and Attributes Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 229. Syngene International Limited Recent Developments Table 230. Aragen Life Sciences Corporation Information Table 231. Aragen Life Sciences Description and Major Businesses Table 232. Aragen Life Sciences Product Features and Attributes Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 234. Aragen Life Sciences Recent Developments Table 235. MabPlex International Corporation Information Table 236. MabPlex International Description and Major Businesses Table 237. MabPlex International Product Features and Attributes Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026) Table 239. MabPlex International Recent Developments Table 240. GenScript Biotech Corporation Corporation Information Table 241. GenScript Biotech Corporation Description and Major Businesses Table 242. GenScript Biotech Corporation Product Features and Attributes Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 244. GenScript Biotech Corporation Recent Developments Table 245. Chime Biologics Corporation Information Table 246. Chime Biologics Description and Major Businesses Table 247. Chime Biologics Product Features and Attributes Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 249. Chime Biologics Recent Developments Table 250. Hangzhou HJB Corporation Information Table 251. Hangzhou HJB Description and Major Businesses Table 252. Hangzhou HJB Product Features and Attributes Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026) Table 254. Hangzhou HJB Recent Developments Table 255. BiBo Pharma Corporation Information Table 256. BiBo Pharma Description and Major Businesses Table 257. BiBo Pharma Product Features and Attributes Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 259. BiBo Pharma Recent Developments Table 260. Technologies, Platforms and Infrastructure Table 261. Distributors List Table 262. Market Trends and Market Evolution Table 263. Market Drivers and Opportunities Table 264. Market Challenges, Risks, and Restraints Table 265. Research Programs/Design for This Report Table 266. Key Data Information from Secondary Sources Table 267. Key Data Information from Primary Sources List of Figures Figure 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Biological Agent Product Picture Figure 3. Biosimilar Drug Product Picture Figure 4. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 5. Drug Substance Manufacturing Product Picture Figure 6. Drug Product Manufacturing Product Picture Figure 7. Integrated Drug Substance and Drug Product Manufacturing Product Picture Figure 8. Others Product Picture Figure 9. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Preclinical and IND-enabling Manufacturing Product Picture Figure 11. Phase I Clinical Manufacturing Product Picture Figure 12. Phase II Clinical Manufacturing Product Picture Figure 13. Phase III Clinical Manufacturing Product Picture Figure 14. Others Product Picture Figure 15. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 16. Oncology Figure 17. Immunology and Autoimmune Diseases Figure 18. Infectious Diseases and Vaccines Figure 19. Metabolic and Endocrine Diseases Figure 20. Neurological Diseases Figure 21. Others Figure 22. Biologics CDMO Report Years Considered Figure 23. Global Biologics CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 24. Global Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 25. Global Biologics CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 26. Global Biologics CDMO Revenue-Based Market Share by Region (2021-2032) Figure 27. Global Biologics CDMO Revenue-Based Market Share Ranking (2025) Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 29. Biological Agent Revenue-Based Market Share by Player in 2025 Figure 30. Biosimilar Drug Revenue-Based Market Share by Player in 2025 Figure 31. Global Biologics CDMO Revenue-Based Market Share by Type (2021-2032) Figure 32. Global Biologics CDMO Revenue-Based Market Share by Manufacturing Service Type (2021-2032) Figure 33. Global Biologics CDMO Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) Figure 34. Global Biologics CDMO Revenue-Based Market Share by Application (2021-2032) Figure 35. North America Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 36. North America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 37. North America Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 38. US Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 39. Canada Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 40. Mexico Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 41. Europe Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 42. Europe Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 43. Europe Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 44. Germany Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 45. France Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 46. U.K. Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 47. Italy Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 48. Russia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 49. Asia-Pacific Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 50. Asia-Pacific Top 8 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 51. Asia-Pacific Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 52. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 53. Japan Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 54. South Korea Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 55. Australia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 56. India Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 57. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 58. Vietnam Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 59. Malaysia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 60. Philippines Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 61. Singapore Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 62. Central and South America Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 63. Central and South America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 64. Central and South America Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 65. Brazil Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 66. Argentina Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 67. Middle East and Africa Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 68. Middle East and Africa Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 69. Middle East and Africa Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 70. GCC Countries Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 71. Israel Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 72. Egypt Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 73. South Africa Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 74. Biologics CDMO Value Chain Mapping Figure 75. Channels of Distribution (Direct Vs Distribution) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed
SummaryThe global Biologics CDMO market is projected to grow from US$ 98436 million in 2025 to US$ 178798 million by 2032, at a CAGR of 8.9% (2026-2032), driven by critical product segments and diverse end‑use applications.Biologics CDMO (Contract Development and Manufacturing Organization) refers to specialized outsourced services that support the development, process optimization, clinical manufacturing, and commercial production of biological pharmaceutical products. These services are provided to biotechnology companies, pharmaceutical manufacturers, and emerging drug developers seeking advanced bioprocessing capabilities and scalable manufacturing infrastructure. The market covers contract development and manufacturing activities for monoclonal antibodies, recombinant proteins, vaccines, antibody-drug conjugates (ADCs), bispecific antibodies, and selected advanced biological therapies. Core services include cell line development, cell banking, upstream and downstream process development, analytical method development, process characterization, formulation development, technology transfer, clinical and commercial drug substance manufacturing, sterile fill-finish, process validation, and quality control. Biologics CDMO operations commonly utilize mammalian cell culture, microbial fermentation, single-use bioreactors, stainless-steel production systems, chromatography purification, filtration technologies, and advanced analytical platforms. Manufacturing and development activities are conducted under applicable Good Manufacturing Practice (GMP) standards and regulatory requirements. The market focuses on integrated development and manufacturing services throughout the biological product lifecycle, enabling pharmaceutical developers to access specialized technologies, reduce internal infrastructure requirements, accelerate clinical development, and establish reliable commercial supply capabilities. Key Findings Biologics CDMO integrates biological process development, clinical manufacturing, and commercial production services Monoclonal antibodies remain a major product category supported by established mammalian cell culture platforms North America, Europe, and Asia-Pacific form the principal regional markets for biologics development and manufacturing outsourcing ADCs and bispecific antibodies are important emerging segments requiring specialized development and manufacturing technologies Market Trends The Biologics CDMO industry is evolving from conventional manufacturing outsourcing toward integrated development and manufacturing partnerships covering the entire biological drug lifecycle. Pharmaceutical and biotechnology companies increasingly prefer service providers capable of supporting cell line development, process optimization, analytical development, clinical production, regulatory validation, and commercial manufacturing within coordinated technology platforms. This approach reduces the operational complexity associated with transferring products between multiple service providers and improves continuity between development and manufacturing stages. Standardized mammalian cell culture platforms, high-performance expression systems, single-use manufacturing technologies, and modular production facilities are improving process flexibility and accelerating project execution. Meanwhile, the growing complexity of ADCs, bispecific antibodies, and other advanced biological modalities is encouraging investment in specialized development capabilities, high-resolution analytical methods, advanced purification technologies, and integrated drug substance and drug product services. Digital process monitoring, automated quality management, artificial intelligence-assisted process optimization, and data-driven manufacturing control are becoming increasingly important for improving production consistency and operational efficiency. As a result, the industry is shifting toward technology-enabled, flexible, and globally coordinated manufacturing networks, with service differentiation increasingly determined by development speed, technical complexity, process robustness, and lifecycle management capabilities. Market Dynamics Drivers The continued expansion of biological drug pipelines is a primary driver of the Biologics CDMO market. Increasing development activity in monoclonal antibodies, recombinant proteins, biosimilars, ADCs, and bispecific antibodies is generating demand for specialized process development and manufacturing services. Emerging biotechnology companies often operate with limited internal production infrastructure and rely on external CDMO partners to support clinical development while controlling capital expenditure. Established pharmaceutical manufacturers also increasingly use outsourcing partnerships to improve capacity flexibility, access specialized technologies, and accelerate product development timelines. The transition of biological drug candidates from early clinical development into late-stage trials and commercial production creates opportunities for service providers to establish longer-term customer relationships. In addition, increasingly stringent regulatory requirements and the technical complexity of biological manufacturing strengthen demand for experienced service providers with validated production platforms, comprehensive quality management systems, and international regulatory capabilities. Restraints The Biologics CDMO industry faces significant capital requirements, long facility construction and qualification cycles, and substantial operating costs. Advanced bioprocessing facilities require specialized equipment, controlled production environments, analytical laboratories, validated utility systems, and experienced scientific and engineering personnel. High fixed costs increase sensitivity to capacity utilization, particularly when clinical manufacturing projects are delayed or commercial production volumes fall below expectations. Development and manufacturing activities also depend on specialized raw materials, culture media, chromatography resins, filtration membranes, and single-use components, which can create procurement and cost pressures. Biological product development involves complex technology transfer, process characterization, and validation procedures, limiting the speed at which projects can move between manufacturing facilities. Additional constraints arise from regulatory approval timelines, intellectual property considerations, and differences in manufacturing requirements across biological modalities. These factors can increase project costs and limit operating flexibility, particularly for smaller service providers. Opportunities Advanced biological therapeutics represent an important growth opportunity for Biologics CDMO providers. ADCs, bispecific and multispecific antibodies, cell and gene therapies, and other complex biological products frequently require specialized development platforms and manufacturing technologies that are expensive for biotechnology developers to establish internally. Service providers offering integrated cell line development, process development, bioconjugation, analytical characterization, drug substance manufacturing, and sterile fill-finish can expand their participation in customer development programs. Biosimilars also create opportunities for CDMO platforms capable of combining high product quality with competitive manufacturing economics. Expansion into late-stage clinical and commercial manufacturing offers additional potential for recurring revenue and longer contractual relationships. Geographical diversification is another strategic opportunity as pharmaceutical companies increasingly evaluate regional production networks to improve supply continuity and address regulatory and geopolitical considerations. Continued adoption of process intensification, continuous bioprocessing, advanced automation, and digital manufacturing tools may further improve productivity and reduce manufacturing costs. Challenges Biologics CDMO providers must manage substantial technical, regulatory, commercial, and operational risks throughout the biological product lifecycle. Clinical development projects are subject to uncertain outcomes, and unsuccessful trials or changes in pharmaceutical development priorities can lead to project cancellations and reduced manufacturing demand. Commercial manufacturing requires consistent quality, process reproducibility, reliable supply, and compliance with increasingly complex international regulatory requirements. Rapid investment in large-scale production facilities can create periods of underutilized capacity and intensify pricing competition when customer demand develops more slowly than anticipated. At the same time, different biological modalities require distinct development and manufacturing technologies, making platform standardization and flexible capacity allocation challenging. International operations are further affected by trade restrictions, cross-border technology transfer requirements, intellectual property considerations, and pharmaceutical supply chain policies. Competition for qualified scientific, engineering, quality assurance, and regulatory personnel also creates operational pressure. Maintaining technological competitiveness while achieving stable utilization and sustainable profitability remains a central challenge for industry participants. Value Chain Analysis The Biologics CDMO value chain extends from upstream technology and raw material suppliers through integrated development and manufacturing service providers to pharmaceutical companies and biological therapy developers. Upstream participants supply cell culture media, expression systems, biological reagents, bioreactors, single-use assemblies, filtration membranes, chromatography resins, analytical instruments, and sterile packaging materials. These inputs directly influence cell growth performance, purification efficiency, process reliability, and manufacturing costs. At the center of the value chain, CDMO providers integrate cell line development, cell banking, process development, analytical characterization, formulation, technology transfer, GMP manufacturing, process validation, and sterile fill-finish. Technical integration between these activities is an important source of value creation because it improves process continuity, reduces repeated development work, and supports more efficient progression from laboratory-scale development to commercial production. Downstream customers consist primarily of biotechnology companies, multinational pharmaceutical manufacturers, biosimilar developers, and specialized biological therapy companies. Their purchasing decisions depend on technical capability, regulatory experience, manufacturing capacity, development timelines, intellectual property protection, and long-term supply reliability. Revenue models typically combine project-based development fees, clinical manufacturing contracts, milestone-related services, and recurring commercial manufacturing agreements. Early-stage development services are generally more dependent on scientific expertise and project execution, while commercial manufacturing requires substantial capital investment and benefits from stable production volumes and high capacity utilization. Specialized services such as complex antibody development, ADC conjugation, and advanced analytical characterization may support differentiated pricing because of their technical requirements. Profitability ultimately depends on project conversion rates, manufacturing yields, fixed-cost absorption, regulatory performance, and the ability to retain customers as products advance through development stages. Segment Insights The Biologics CDMO market can be analyzed through biological product type, development and manufacturing service, production technology, and clinical development stage. Monoclonal antibodies represent a major established product segment because of their broad therapeutic applications, mature expression technologies, and extensive clinical and commercial manufacturing requirements. Recombinant proteins and biosimilars represent additional established markets, with customer demand emphasizing process robustness, product consistency, and cost-effective large-scale production. Mammalian cell culture remains a key production technology for complex therapeutic proteins, particularly products requiring specific post-translational modifications. Microbial expression systems remain important for selected recombinant proteins and biological products. The appropriate manufacturing platform depends on molecular structure, biological activity, production scale, quality requirements, and process economics. From a service perspective, development services and manufacturing services have different commercial characteristics but are increasingly connected within integrated CDMO business models. Cell line development, analytical development, and process optimization establish the technical foundation for later production activities, while clinical manufacturing supports investigational product supply and regulatory progression. Commercial manufacturing provides opportunities for longer-term contracts and recurring production revenue, although conversion from clinical projects remains dependent on successful development and regulatory approval. Drug substance manufacturing represents a technically intensive part of the market, while sterile fill-finish and formulation services are gaining strategic importance as customers seek integrated production solutions. ADCs and bispecific antibodies represent important specialized segments, requiring additional capabilities in molecular characterization, conjugation, purification, and product stability management. Providers capable of integrating these specialized technologies into scalable manufacturing platforms are positioned to capture higher-value development and manufacturing projects. Downstream Market Opportunities Downstream demand for Biologics CDMO services is primarily associated with oncology, immunology, inflammatory diseases, infectious diseases, rare diseases, and other therapeutic areas involving biological medicines. Oncology represents an important opportunity because the development of monoclonal antibodies, bispecific antibodies, and ADCs creates complex process development, analytical testing, and commercial manufacturing requirements. Immunology and chronic inflammatory disease therapies support demand for established biological manufacturing platforms and reliable long-term commercial supply. Biosimilar developers increasingly require CDMO partners that can maintain consistent product quality while reducing production costs and supporting market entry. Emerging biotechnology enterprises represent another important customer group, particularly when advancing drug candidates from preclinical research into clinical development and commercial preparation. These companies frequently rely on external service providers for cell line development, process characterization, GMP production, and regulatory manufacturing support. As biological drug pipelines become more diverse, CDMO providers with integrated development, clinical manufacturing, and commercial supply capabilities have opportunities to increase customer engagement across multiple product stages and therapeutic applications. Regional Insights North America represents one of the principal regional markets for Biologics CDMO services, supported by its extensive biotechnology ecosystem, established pharmaceutical industry, and substantial biological drug development activity. The United States is particularly important for innovative therapeutic development, early-stage biotechnology outsourcing, and advanced biological manufacturing technologies. Regional pharmaceutical customers place significant emphasis on regulatory compliance, manufacturing quality, intellectual property protection, and supply chain resilience. Continued investment in domestic manufacturing infrastructure is strengthening the region's capacity to support commercial-scale biological drug production. Europe also maintains a strong position in the Biologics CDMO industry, supported by established pharmaceutical production capabilities, advanced bioprocessing technologies, and mature regulatory systems. Switzerland, Germany, Ireland, and other European manufacturing locations serve international customers through specialized biological production facilities and integrated development and manufacturing networks. Asia-Pacific is an important region for manufacturing capacity expansion, technology investment, and the development of integrated biologics services. South Korea has established substantial large-scale mammalian cell culture capacity and a strong presence in commercial biological manufacturing. China has developed broad service capabilities spanning biological research support, cell line development, process optimization, clinical manufacturing, and commercial production. Japan and Singapore contribute specialized manufacturing technologies, experienced pharmaceutical production infrastructure, and high-quality regulatory manufacturing capabilities. Regional competitiveness increasingly reflects differences in manufacturing scale, technical specialization, operating efficiency, international regulatory experience, and access to global pharmaceutical customers. Latin America and the Middle East represent smaller but developing opportunities, particularly in vaccine production, regional pharmaceutical supply, technology transfer, and localized biological manufacturing. Across regions, pharmaceutical companies are increasingly evaluating manufacturing partnerships based on regulatory compatibility, geographical diversification, and long-term operational reliability. Competitive Landscape Analysis The Biologics CDMO market is characterized by competition between large integrated multinational service providers and specialized companies focusing on particular biological modalities, development technologies, or manufacturing processes. Established industry participants include Lonza, Samsung Biologics, WuXi Biologics, and FUJIFILM Biotechnologies, each with differentiated operating capabilities and strategic priorities. Lonza operates an extensive biological development and manufacturing platform covering mammalian and microbial production, bioconjugation, and drug product manufacturing. Its global manufacturing infrastructure and technical expertise support customers across multiple stages of biological drug development and commercialization. Samsung Biologics emphasizes large-scale mammalian cell culture manufacturing, standardized production platforms, and integrated contract development and manufacturing services, positioning its operations around manufacturing efficiency, quality control, and long-term commercial partnerships. WuXi Biologics provides integrated biological development and manufacturing services, with particular exposure to monoclonal antibodies, bispecific antibodies, and ADC-related programs. In 2025, the company reported 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects, while adding 209 new integrated projects during the year. Approximately two-thirds of these new projects involved bispecific antibodies and ADCs, illustrating the increasing importance of complex biological modalities. FUJIFILM Biotechnologies is expanding commercial-scale manufacturing capabilities through its international production network. Its Holly Springs facility in North Carolina opened in September 2025 with an initial configuration of eight 20,000-liter mammalian cell culture bioreactors, strengthening its large-scale manufacturing capabilities. Overall, industry competition increasingly centers on integrated service coverage, technical specialization, regulatory execution, capacity utilization, manufacturing quality, and customer lifecycle management. Large providers benefit from established infrastructure and international production networks, while specialized CDMOs compete through flexibility, innovative technology platforms, and expertise in complex biological products. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics CDMO market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends. Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company Lonza Group AG Samsung Biologics Co., Ltd. WuXi Biologics (Cayman) Inc. FUJIFILM Holdings Corporation AGC Inc. Boehringer Ingelheim International GmbH Thermo Fisher Scientific Inc. Novo Holdings A/S Rentschler Biopharma SE KBI Biopharma, Inc. Ajinomoto Co., Inc. LOTTE BIOLOGICS Polpharma Biologics EirGenix, Inc. Richter-Helm BioLogics GmbH & Co. KG Simtra BioPharma Solutions Vetter Pharma-Fertigung GmbH & Co. KG Piramal Pharma Limited AbbVie Inc. Emergent BioSolutions Inc. SK pharmteco Oxford Biomedica plc WuXi XDC Cayman Inc. Porton Pharma Solutions Ltd. Asymchem Laboratories (Tianjin) Co., Ltd. BioVectra Inc. Bora Pharmaceuticals Co., Ltd. Recipharm AB Minaris Regenerative Medicine Cellipont Bioservices Andelyn Biosciences Danaher Corporation BioCina Syngene International Limited Aragen Life Sciences MabPlex International GenScript Biotech Corporation Chime Biologics Hangzhou HJB BiBo Pharma Segment by Type Biological Agent Biosimilar Drug Segment by Manufacturing Service Type Drug Substance Manufacturing Drug Product Manufacturing Integrated Drug Substance and Drug Product Manufacturing Others Segment by Development and Commercialization Stage Preclinical and IND-enabling Manufacturing Phase I Clinical Manufacturing Phase II Clinical Manufacturing Phase III Clinical Manufacturing Others Segment by Application Oncology Immunology and Autoimmune Diseases Infectious Diseases and Vaccines Metabolic and Endocrine Diseases Neurological Diseases Others Segment by Region North America United States Canada Mexico Asia-Pacific China Japan South Korea India Australia Vietnam Indonesia Malaysia Philippines Singapore Rest of Asia Europe Germany U.K. France Italy Spain Benelux Russia Rest of Europe Central and South America Brazil Argentina Rest of Central and South America Middle East & Africa GCC Countries Egypt Israel South Africa Rest of MEA Chapter Outline Chapter 1: Defines the Biologics CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage. Table of Contents1 Study Coverage1.1 Introduction to Biologics CDMO: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global Biologics CDMO Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 Biological Agent 1.2.3 Biosimilar Drug 1.3 Market Segmentation by Manufacturing Service Type 1.3.1 Global Biologics CDMO Market Size by Manufacturing Service Type, 2021 vs 2025 vs 2032 1.3.2 Drug Substance Manufacturing 1.3.3 Drug Product Manufacturing 1.3.4 Integrated Drug Substance and Drug Product Manufacturing 1.3.5 Others 1.4 Market Segmentation by Development and Commercialization Stage 1.4.1 Global Biologics CDMO Market Size by Development and Commercialization Stage, 2021 vs 2025 vs 2032 1.4.2 Preclinical and IND-enabling Manufacturing 1.4.3 Phase I Clinical Manufacturing 1.4.4 Phase II Clinical Manufacturing 1.4.5 Phase III Clinical Manufacturing 1.4.6 Others 1.5 Market Segmentation by Application 1.5.1 Global Biologics CDMO Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Oncology 1.5.3 Immunology and Autoimmune Diseases 1.5.4 Infectious Diseases and Vaccines 1.5.5 Metabolic and Endocrine Diseases 1.5.6 Neurological Diseases 1.5.7 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Biologics CDMO Revenue Estimates and Forecasts (2021-2032) 2.2 Global Biologics CDMO Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends 3 Competitive Landscape 3.1 Global Biologics CDMO Players’ Revenue Rankings and Profitability 3.1.1 Global Revenue (Value) by Players (2021-2026) 3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025) 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.1.4 Gross Margin by Top Players (2021 vs 2025) 3.2 Global Biologics CDMO Companies Headquarters and Service Footprint 3.3 Key Player Market Share by Product Type 3.3.1 Biological Agent: Market Share by Key Players 3.3.2 Biosimilar Drug: Market Share by Key Players 3.4 Global Biologics CDMO Market Concentration and Dynamics 3.4.1 Global Market Concentration 3.4.2 Market Entry and Exit Analysis 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment 4 Product Segmentation 4.1 Global Biologics CDMO Market by Type 4.1.1 Global Revenue by Type (2021-2032) 4.1.2 Global Revenue-Based Market Share by Type (2021-2032) 4.2 Global Biologics CDMO Market by Manufacturing Service Type 4.2.1 Global Revenue by Manufacturing Service Type (2021-2032) 4.2.2 Global Revenue-Based Market Share by Manufacturing Service Type (2021-2032) 4.3 Global Biologics CDMO Market by Development and Commercialization Stage 4.3.1 Global Revenue by Development and Commercialization Stage (2021-2032) 4.3.2 Global Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) 4.4 Key Product Attributes and Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global Biologics CDMO Revenue by Application 5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.1.2 Revenue-Based Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Downstream Customer Analysis 5.2.1 Top Customers by Region 5.2.2 Top Customers by Application 6 North America 6.1 North America Market Size (2021-2032) 6.2 North America Key Players’ Revenue in 2025 6.3 North America Biologics CDMO Market Size by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America Biologics CDMO Market Size by Country 6.5.1 North America Revenue Trends by Country 6.5.2 US 6.5.3 Canada 6.5.4 Mexico 7 Europe 7.1 Europe Market Size (2021-2032) 7.2 Europe Key Players’ Revenue in 2025 7.3 Europe Biologics CDMO Market Size by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe Biologics CDMO Market Size by Country 7.5.1 Europe Revenue Trends by Country 7.5.2 Germany 7.5.3 France 7.5.4 U.K. 7.5.5 Italy 7.5.6 Russia 8 Asia-Pacific 8.1 Asia-Pacific Market Size (2021-2032) 8.2 Asia-Pacific Key Players’ Revenue in 2025 8.3 Asia-Pacific Biologics CDMO Market Size by Application (2021-2032) 8.4 Asia-Pacific Growth Accelerators and Market Barriers 8.5 Asia-Pacific Biologics CDMO Market Size by Region 8.5.1 Asia-Pacific Revenue Trends by Region 8.6 China 8.7 Japan 8.8 South Korea 8.9 Australia 8.10 India 8.11 Southeast Asia 8.11.1 Indonesia 8.11.2 Vietnam 8.11.3 Malaysia 8.11.4 Philippines 8.11.5 Singapore 9 Central and South America 9.1 Central and South America Market Size (2021-2032) 9.2 Central and South America Key Players’ Revenue in 2025 9.3 Central and South America Biologics CDMO Market Size by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America Biologics CDMO Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Market Size (2021-2032) 10.2 Middle East and Africa Key Players’ Revenue in 2025 10.3 Middle East and Africa Biologics CDMO Market Size by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa Biologics CDMO Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Israel 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 Lonza Group AG 11.1.1 Lonza Group AG Corporation Information 11.1.2 Lonza Group AG Business Overview 11.1.3 Lonza Group AG Biologics CDMO Product Features and Attributes 11.1.4 Lonza Group AG Biologics CDMO Revenue and Gross Margin (2021-2026) 11.1.5 Lonza Group AG Biologics CDMO Revenue by Product in 2025 11.1.6 Lonza Group AG Biologics CDMO Revenue by Application in 2025 11.1.7 Lonza Group AG Biologics CDMO Revenue by Geographic Area in 2025 11.1.8 Lonza Group AG Biologics CDMO SWOT Analysis 11.1.9 Lonza Group AG Recent Developments 11.2 Samsung Biologics Co., Ltd. 11.2.1 Samsung Biologics Co., Ltd. Corporation Information 11.2.2 Samsung Biologics Co., Ltd. Business Overview 11.2.3 Samsung Biologics Co., Ltd. Biologics CDMO Product Features and Attributes 11.2.4 Samsung Biologics Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.2.5 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Product in 2025 11.2.6 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Application in 2025 11.2.7 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Geographic Area in 2025 11.2.8 Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis 11.2.9 Samsung Biologics Co., Ltd. Recent Developments 11.3 WuXi Biologics (Cayman) Inc. 11.3.1 WuXi Biologics (Cayman) Inc. Corporation Information 11.3.2 WuXi Biologics (Cayman) Inc. Business Overview 11.3.3 WuXi Biologics (Cayman) Inc. Biologics CDMO Product Features and Attributes 11.3.4 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.3.5 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Product in 2025 11.3.6 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Application in 2025 11.3.7 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Geographic Area in 2025 11.3.8 WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis 11.3.9 WuXi Biologics (Cayman) Inc. Recent Developments 11.4 FUJIFILM Holdings Corporation 11.4.1 FUJIFILM Holdings Corporation Corporation Information 11.4.2 FUJIFILM Holdings Corporation Business Overview 11.4.3 FUJIFILM Holdings Corporation Biologics CDMO Product Features and Attributes 11.4.4 FUJIFILM Holdings Corporation Biologics CDMO Revenue and Gross Margin (2021-2026) 11.4.5 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Product in 2025 11.4.6 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Application in 2025 11.4.7 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Geographic Area in 2025 11.4.8 FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis 11.4.9 FUJIFILM Holdings Corporation Recent Developments 11.5 AGC Inc. 11.5.1 AGC Inc. Corporation Information 11.5.2 AGC Inc. Business Overview 11.5.3 AGC Inc. Biologics CDMO Product Features and Attributes 11.5.4 AGC Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.5.5 AGC Inc. Biologics CDMO Revenue by Product in 2025 11.5.6 AGC Inc. Biologics CDMO Revenue by Application in 2025 11.5.7 AGC Inc. Biologics CDMO Revenue by Geographic Area in 2025 11.5.8 AGC Inc. Biologics CDMO SWOT Analysis 11.5.9 AGC Inc. Recent Developments 11.6 Boehringer Ingelheim International GmbH 11.6.1 Boehringer Ingelheim International GmbH Corporation Information 11.6.2 Boehringer Ingelheim International GmbH Business Overview 11.6.3 Boehringer Ingelheim International GmbH Biologics CDMO Product Features and Attributes 11.6.4 Boehringer Ingelheim International GmbH Biologics CDMO Revenue and Gross Margin (2021-2026) 11.6.5 Boehringer Ingelheim International GmbH Recent Developments 11.7 Thermo Fisher Scientific Inc. 11.7.1 Thermo Fisher Scientific Inc. Corporation Information 11.7.2 Thermo Fisher Scientific Inc. Business Overview 11.7.3 Thermo Fisher Scientific Inc. Biologics CDMO Product Features and Attributes 11.7.4 Thermo Fisher Scientific Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.7.5 Thermo Fisher Scientific Inc. Recent Developments 11.8 Novo Holdings A/S 11.8.1 Novo Holdings A/S Corporation Information 11.8.2 Novo Holdings A/S Business Overview 11.8.3 Novo Holdings A/S Biologics CDMO Product Features and Attributes 11.8.4 Novo Holdings A/S Biologics CDMO Revenue and Gross Margin (2021-2026) 11.8.5 Novo Holdings A/S Recent Developments 11.9 Rentschler Biopharma SE 11.9.1 Rentschler Biopharma SE Corporation Information 11.9.2 Rentschler Biopharma SE Business Overview 11.9.3 Rentschler Biopharma SE Biologics CDMO Product Features and Attributes 11.9.4 Rentschler Biopharma SE Biologics CDMO Revenue and Gross Margin (2021-2026) 11.9.5 Rentschler Biopharma SE Recent Developments 11.10 KBI Biopharma, Inc. 11.10.1 KBI Biopharma, Inc. Corporation Information 11.10.2 KBI Biopharma, Inc. Business Overview 11.10.3 KBI Biopharma, Inc. Biologics CDMO Product Features and Attributes 11.10.4 KBI Biopharma, Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.10.5 Company Ten Recent Developments 11.11 Ajinomoto Co., Inc. 11.11.1 Ajinomoto Co., Inc. Corporation Information 11.11.2 Ajinomoto Co., Inc. Business Overview 11.11.3 Ajinomoto Co., Inc. Biologics CDMO Product Features and Attributes 11.11.4 Ajinomoto Co., Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.11.5 Ajinomoto Co., Inc. Recent Developments 11.12 LOTTE BIOLOGICS 11.12.1 LOTTE BIOLOGICS Corporation Information 11.12.2 LOTTE BIOLOGICS Business Overview 11.12.3 LOTTE BIOLOGICS Biologics CDMO Product Features and Attributes 11.12.4 LOTTE BIOLOGICS Biologics CDMO Revenue and Gross Margin (2021-2026) 11.12.5 LOTTE BIOLOGICS Recent Developments 11.13 Polpharma Biologics 11.13.1 Polpharma Biologics Corporation Information 11.13.2 Polpharma Biologics Business Overview 11.13.3 Polpharma Biologics Biologics CDMO Product Features and Attributes 11.13.4 Polpharma Biologics Biologics CDMO Revenue and Gross Margin (2021-2026) 11.13.5 Polpharma Biologics Recent Developments 11.14 EirGenix, Inc. 11.14.1 EirGenix, Inc. Corporation Information 11.14.2 EirGenix, Inc. Business Overview 11.14.3 EirGenix, Inc. Biologics CDMO Product Features and Attributes 11.14.4 EirGenix, Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.14.5 EirGenix, Inc. Recent Developments 11.15 Richter-Helm BioLogics GmbH & Co. KG 11.15.1 Richter-Helm BioLogics GmbH & Co. KG Corporation Information 11.15.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview 11.15.3 Richter-Helm BioLogics GmbH & Co. KG Biologics CDMO Product Features and Attributes 11.15.4 Richter-Helm BioLogics GmbH & Co. KG Biologics CDMO Revenue and Gross Margin (2021-2026) 11.15.5 Richter-Helm BioLogics GmbH & Co. KG Recent Developments 11.16 Simtra BioPharma Solutions 11.16.1 Simtra BioPharma Solutions Corporation Information 11.16.2 Simtra BioPharma Solutions Business Overview 11.16.3 Simtra BioPharma Solutions Biologics CDMO Product Features and Attributes 11.16.4 Simtra BioPharma Solutions Biologics CDMO Revenue and Gross Margin (2021-2026) 11.16.5 Simtra BioPharma Solutions Recent Developments 11.17 Vetter Pharma-Fertigung GmbH & Co. KG 11.17.1 Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information 11.17.2 Vetter Pharma-Fertigung GmbH & Co. KG Business Overview 11.17.3 Vetter Pharma-Fertigung GmbH & Co. KG Biologics CDMO Product Features and Attributes 11.17.4 Vetter Pharma-Fertigung GmbH & Co. KG Biologics CDMO Revenue and Gross Margin (2021-2026) 11.17.5 Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments 11.18 Piramal Pharma Limited 11.18.1 Piramal Pharma Limited Corporation Information 11.18.2 Piramal Pharma Limited Business Overview 11.18.3 Piramal Pharma Limited Biologics CDMO Product Features and Attributes 11.18.4 Piramal Pharma Limited Biologics CDMO Revenue and Gross Margin (2021-2026) 11.18.5 Piramal Pharma Limited Recent Developments 11.19 AbbVie Inc. 11.19.1 AbbVie Inc. Corporation Information 11.19.2 AbbVie Inc. Business Overview 11.19.3 AbbVie Inc. Biologics CDMO Product Features and Attributes 11.19.4 AbbVie Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.19.5 AbbVie Inc. Recent Developments 11.20 Emergent BioSolutions Inc. 11.20.1 Emergent BioSolutions Inc. Corporation Information 11.20.2 Emergent BioSolutions Inc. Business Overview 11.20.3 Emergent BioSolutions Inc. Biologics CDMO Product Features and Attributes 11.20.4 Emergent BioSolutions Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.20.5 Emergent BioSolutions Inc. Recent Developments 11.21 SK pharmteco 11.21.1 SK pharmteco Corporation Information 11.21.2 SK pharmteco Business Overview 11.21.3 SK pharmteco Biologics CDMO Product Features and Attributes 11.21.4 SK pharmteco Biologics CDMO Revenue and Gross Margin (2021-2026) 11.21.5 SK pharmteco Recent Developments 11.22 Oxford Biomedica plc 11.22.1 Oxford Biomedica plc Corporation Information 11.22.2 Oxford Biomedica plc Business Overview 11.22.3 Oxford Biomedica plc Biologics CDMO Product Features and Attributes 11.22.4 Oxford Biomedica plc Biologics CDMO Revenue and Gross Margin (2021-2026) 11.22.5 Oxford Biomedica plc Recent Developments 11.23 WuXi XDC Cayman Inc. 11.23.1 WuXi XDC Cayman Inc. Corporation Information 11.23.2 WuXi XDC Cayman Inc. Business Overview 11.23.3 WuXi XDC Cayman Inc. Biologics CDMO Product Features and Attributes 11.23.4 WuXi XDC Cayman Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.23.5 WuXi XDC Cayman Inc. Recent Developments 11.24 Porton Pharma Solutions Ltd. 11.24.1 Porton Pharma Solutions Ltd. Corporation Information 11.24.2 Porton Pharma Solutions Ltd. Business Overview 11.24.3 Porton Pharma Solutions Ltd. Biologics CDMO Product Features and Attributes 11.24.4 Porton Pharma Solutions Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.24.5 Porton Pharma Solutions Ltd. Recent Developments 11.25 Asymchem Laboratories (Tianjin) Co., Ltd. 11.25.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information 11.25.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview 11.25.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics CDMO Product Features and Attributes 11.25.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.25.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments 11.26 BioVectra Inc. 11.26.1 BioVectra Inc. Corporation Information 11.26.2 BioVectra Inc. Business Overview 11.26.3 BioVectra Inc. Biologics CDMO Product Features and Attributes 11.26.4 BioVectra Inc. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.26.5 BioVectra Inc. Recent Developments 11.27 Bora Pharmaceuticals Co., Ltd. 11.27.1 Bora Pharmaceuticals Co., Ltd. Corporation Information 11.27.2 Bora Pharmaceuticals Co., Ltd. Business Overview 11.27.3 Bora Pharmaceuticals Co., Ltd. Biologics CDMO Product Features and Attributes 11.27.4 Bora Pharmaceuticals Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026) 11.27.5 Bora Pharmaceuticals Co., Ltd. Recent Developments 11.28 Recipharm AB 11.28.1 Recipharm AB Corporation Information 11.28.2 Recipharm AB Business Overview 11.28.3 Recipharm AB Biologics CDMO Product Features and Attributes 11.28.4 Recipharm AB Biologics CDMO Revenue and Gross Margin (2021-2026) 11.28.5 Recipharm AB Recent Developments 11.29 Minaris Regenerative Medicine 11.29.1 Minaris Regenerative Medicine Corporation Information 11.29.2 Minaris Regenerative Medicine Business Overview 11.29.3 Minaris Regenerative Medicine Biologics CDMO Product Features and Attributes 11.29.4 Minaris Regenerative Medicine Biologics CDMO Revenue and Gross Margin (2021-2026) 11.29.5 Minaris Regenerative Medicine Recent Developments 11.30 Cellipont Bioservices 11.30.1 Cellipont Bioservices Corporation Information 11.30.2 Cellipont Bioservices Business Overview 11.30.3 Cellipont Bioservices Biologics CDMO Product Features and Attributes 11.30.4 Cellipont Bioservices Biologics CDMO Revenue and Gross Margin (2021-2026) 11.30.5 Cellipont Bioservices Recent Developments 11.31 Andelyn Biosciences 11.31.1 Andelyn Biosciences Corporation Information 11.31.2 Andelyn Biosciences Business Overview 11.31.3 Andelyn Biosciences Biologics CDMO Product Features and Attributes 11.31.4 Andelyn Biosciences Biologics CDMO Revenue and Gross Margin (2021-2026) 11.31.5 Andelyn Biosciences Recent Developments 11.32 Danaher Corporation 11.32.1 Danaher Corporation Corporation Information 11.32.2 Danaher Corporation Business Overview 11.32.3 Danaher Corporation Biologics CDMO Product Features and Attributes 11.32.4 Danaher Corporation Biologics CDMO Revenue and Gross Margin (2021-2026) 11.32.5 Danaher Corporation Recent Developments 11.33 BioCina 11.33.1 BioCina Corporation Information 11.33.2 BioCina Business Overview 11.33.3 BioCina Biologics CDMO Product Features and Attributes 11.33.4 BioCina Biologics CDMO Revenue and Gross Margin (2021-2026) 11.33.5 BioCina Recent Developments 11.34 Syngene International Limited 11.34.1 Syngene International Limited Corporation Information 11.34.2 Syngene International Limited Business Overview 11.34.3 Syngene International Limited Biologics CDMO Product Features and Attributes 11.34.4 Syngene International Limited Biologics CDMO Revenue and Gross Margin (2021-2026) 11.34.5 Syngene International Limited Recent Developments 11.35 Aragen Life Sciences 11.35.1 Aragen Life Sciences Corporation Information 11.35.2 Aragen Life Sciences Business Overview 11.35.3 Aragen Life Sciences Biologics CDMO Product Features and Attributes 11.35.4 Aragen Life Sciences Biologics CDMO Revenue and Gross Margin (2021-2026) 11.35.5 Aragen Life Sciences Recent Developments 11.36 MabPlex International 11.36.1 MabPlex International Corporation Information 11.36.2 MabPlex International Business Overview 11.36.3 MabPlex International Biologics CDMO Product Features and Attributes 11.36.4 MabPlex International Biologics CDMO Revenue and Gross Margin (2021-2026) 11.36.5 MabPlex International Recent Developments 11.37 GenScript Biotech Corporation 11.37.1 GenScript Biotech Corporation Corporation Information 11.37.2 GenScript Biotech Corporation Business Overview 11.37.3 GenScript Biotech Corporation Biologics CDMO Product Features and Attributes 11.37.4 GenScript Biotech Corporation Biologics CDMO Revenue and Gross Margin (2021-2026) 11.37.5 GenScript Biotech Corporation Recent Developments 11.38 Chime Biologics 11.38.1 Chime Biologics Corporation Information 11.38.2 Chime Biologics Business Overview 11.38.3 Chime Biologics Biologics CDMO Product Features and Attributes 11.38.4 Chime Biologics Biologics CDMO Revenue and Gross Margin (2021-2026) 11.38.5 Chime Biologics Recent Developments 11.39 Hangzhou HJB 11.39.1 Hangzhou HJB Corporation Information 11.39.2 Hangzhou HJB Business Overview 11.39.3 Hangzhou HJB Biologics CDMO Product Features and Attributes 11.39.4 Hangzhou HJB Biologics CDMO Revenue and Gross Margin (2021-2026) 11.39.5 Hangzhou HJB Recent Developments 11.40 BiBo Pharma 11.40.1 BiBo Pharma Corporation Information 11.40.2 BiBo Pharma Business Overview 11.40.3 BiBo Pharma Biologics CDMO Product Features and Attributes 11.40.4 BiBo Pharma Biologics CDMO Revenue and Gross Margin (2021-2026) 11.40.5 BiBo Pharma Recent Developments 12 Biologics CDMO Value Chain and Ecosystem Analysis 12.1 Biologics CDMO Value Chain (Ecosystem Structure) 12.2 Upstream Analysis 12.2.1 Key Technologies, Platforms and Infrastructure 12.3 Midstream Analysis 12.4 Downstream Sales Model and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 Biologics CDMO Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 14 Key Findings in the Global Biologics CDMO Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details List of Tables/GraphsList of TablesTable 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Biologics CDMO Revenue by Region (US$ Million), 2021-2026 Table 7. Global Biologics CDMO Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Biologics CDMO Revenue by Players (US$ Million), 2021-2026 Table 10. Global Biologics CDMO Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics CDMO Revenue, 2025 Table 13. Global Biologics CDMO Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Biologics CDMO Companies Headquarters Table 15. Global Biologics CDMO Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Biologics CDMO Revenue by Type (US$ Million), 2021-2026 Table 19. Global Biologics CDMO Revenue by Type (US$ Million), 2027-2032 Table 20. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2021-2026 Table 21. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2027-2032 Table 22. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2021-2026 Table 23. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Biologics CDMO Revenue by Application (US$ Million), 2021-2026 Table 26. Global Biologics CDMO Revenue by Application (US$ Million), 2027-2032 Table 27. Biologics CDMO High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Biologics CDMO Growth Accelerators and Market Barriers Table 31. North America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Biologics CDMO Growth Accelerators and Market Barriers Table 33. Europe Biologics CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Biologics CDMO Growth Accelerators and Market Barriers Table 35. Asia-Pacific Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Biologics CDMO Investment Opportunities and Key Challenges Table 37. Central and South America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Biologics CDMO Investment Opportunities and Key Challenges Table 39. Middle East and Africa Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Lonza Group AG Corporation Information Table 41. Lonza Group AG Description and Major Businesses Table 42. Lonza Group AG Product Features and Attributes Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Group AG Revenue Proportion by Product in 2025 Table 45. Lonza Group AG Revenue Proportion by Application in 2025 Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025 Table 47. Lonza Group AG Biologics CDMO SWOT Analysis Table 48. Lonza Group AG Recent Developments Table 49. Samsung Biologics Co., Ltd. Corporation Information Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025 Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025 Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025 Table 56. Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis Table 57. Samsung Biologics Co., Ltd. Recent Developments Table 58. WuXi Biologics (Cayman) Inc. Corporation Information Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025 Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025 Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025 Table 65. WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis Table 66. WuXi Biologics (Cayman) Inc. Recent Developments Table 67. FUJIFILM Holdings Corporation Corporation Information Table 68. FUJIFILM Holdings Corporation Description and Major Businesses Table 69. FUJIFILM Holdings Corporation Product Features and Attributes Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025 Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025 Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025 Table 74. FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis Table 75. FUJIFILM Holdings Corporation Recent Developments Table 76. AGC Inc. Corporation Information Table 77. AGC Inc. Description and Major Businesses Table 78. AGC Inc. Product Features and Attributes Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AGC Inc. Revenue Proportion by Product in 2025 Table 81. AGC Inc. Revenue Proportion by Application in 2025 Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025 Table 83. AGC Inc. Biologics CDMO SWOT Analysis Table 84. AGC Inc. Recent Developments Table 85. Boehringer Ingelheim International GmbH Corporation Information Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim International GmbH Recent Developments Table 90. Thermo Fisher Scientific Inc. Corporation Information Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Thermo Fisher Scientific Inc. Recent Developments Table 95. Novo Holdings A/S Corporation Information Table 96. Novo Holdings A/S Description and Major Businesses Table 97. Novo Holdings A/S Product Features and Attributes Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novo Holdings A/S Recent Developments Table 100. Rentschler Biopharma SE Corporation Information Table 101. Rentschler Biopharma SE Description and Major Businesses Table 102. Rentschler Biopharma SE Product Features and Attributes Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Rentschler Biopharma SE Recent Developments Table 105. KBI Biopharma, Inc. Corporation Information Table 106. KBI Biopharma, Inc. Description and Major Businesses Table 107. KBI Biopharma, Inc. Product Features and Attributes Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. KBI Biopharma, Inc. Recent Developments Table 110. Ajinomoto Co., Inc. Corporation Information Table 111. Ajinomoto Co., Inc. Description and Major Businesses Table 112. Ajinomoto Co., Inc. Product Features and Attributes Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ajinomoto Co., Inc. Recent Developments Table 115. LOTTE BIOLOGICS Corporation Information Table 116. LOTTE BIOLOGICS Description and Major Businesses Table 117. LOTTE BIOLOGICS Product Features and Attributes Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. LOTTE BIOLOGICS Recent Developments Table 120. Polpharma Biologics Corporation Information Table 121. Polpharma Biologics Description and Major Businesses Table 122. Polpharma Biologics Product Features and Attributes Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Polpharma Biologics Recent Developments Table 125. EirGenix, Inc. Corporation Information Table 126. EirGenix, Inc. Description and Major Businesses Table 127. EirGenix, Inc. Product Features and Attributes Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. EirGenix, Inc. Recent Developments Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments Table 135. Simtra BioPharma Solutions Corporation Information Table 136. Simtra BioPharma Solutions Description and Major Businesses Table 137. Simtra BioPharma Solutions Product Features and Attributes Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Simtra BioPharma Solutions Recent Developments Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments Table 145. Piramal Pharma Limited Corporation Information Table 146. Piramal Pharma Limited Description and Major Businesses Table 147. Piramal Pharma Limited Product Features and Attributes Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Piramal Pharma Limited Recent Developments Table 150. AbbVie Inc. Corporation Information Table 151. AbbVie Inc. Description and Major Businesses Table 152. AbbVie Inc. Product Features and Attributes Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. AbbVie Inc. Recent Developments Table 155. Emergent BioSolutions Inc. Corporation Information Table 156. Emergent BioSolutions Inc. Description and Major Businesses Table 157. Emergent BioSolutions Inc. Product Features and Attributes Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Emergent BioSolutions Inc. Recent Developments Table 160. SK pharmteco Corporation Information Table 161. SK pharmteco Description and Major Businesses Table 162. SK pharmteco Product Features and Attributes Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. SK pharmteco Recent Developments Table 165. Oxford Biomedica plc Corporation Information Table 166. Oxford Biomedica plc Description and Major Businesses Table 167. Oxford Biomedica plc Product Features and Attributes Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Oxford Biomedica plc Recent Developments Table 170. WuXi XDC Cayman Inc. Corporation Information Table 171. WuXi XDC Cayman Inc. Description and Major Businesses Table 172. WuXi XDC Cayman Inc. Product Features and Attributes Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. WuXi XDC Cayman Inc. Recent Developments Table 175. Porton Pharma Solutions Ltd. Corporation Information Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. Porton Pharma Solutions Ltd. Recent Developments Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments Table 185. BioVectra Inc. Corporation Information Table 186. BioVectra Inc. Description and Major Businesses Table 187. BioVectra Inc. Product Features and Attributes Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. BioVectra Inc. Recent Developments Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026) Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments Table 195. Recipharm AB Corporation Information Table 196. Recipharm AB Description and Major Businesses Table 197. Recipharm AB Product Features and Attributes Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026) Table 199. Recipharm AB Recent Developments Table 200. Minaris Regenerative Medicine Corporation Information Table 201. Minaris Regenerative Medicine Description and Major Businesses Table 202. Minaris Regenerative Medicine Product Features and Attributes Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 204. Minaris Regenerative Medicine Recent Developments Table 205. Cellipont Bioservices Corporation Information Table 206. Cellipont Bioservices Description and Major Businesses Table 207. Cellipont Bioservices Product Features and Attributes Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026) Table 209. Cellipont Bioservices Recent Developments Table 210. Andelyn Biosciences Corporation Information Table 211. Andelyn Biosciences Description and Major Businesses Table 212. Andelyn Biosciences Product Features and Attributes Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 214. Andelyn Biosciences Recent Developments Table 215. Danaher Corporation Corporation Information Table 216. Danaher Corporation Description and Major Businesses Table 217. Danaher Corporation Product Features and Attributes Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 219. Danaher Corporation Recent Developments Table 220. BioCina Corporation Information Table 221. BioCina Description and Major Businesses Table 222. BioCina Product Features and Attributes Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026) Table 224. BioCina Recent Developments Table 225. Syngene International Limited Corporation Information Table 226. Syngene International Limited Description and Major Businesses Table 227. Syngene International Limited Product Features and Attributes Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026) Table 229. Syngene International Limited Recent Developments Table 230. Aragen Life Sciences Corporation Information Table 231. Aragen Life Sciences Description and Major Businesses Table 232. Aragen Life Sciences Product Features and Attributes Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 234. Aragen Life Sciences Recent Developments Table 235. MabPlex International Corporation Information Table 236. MabPlex International Description and Major Businesses Table 237. MabPlex International Product Features and Attributes Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026) Table 239. MabPlex International Recent Developments Table 240. GenScript Biotech Corporation Corporation Information Table 241. GenScript Biotech Corporation Description and Major Businesses Table 242. GenScript Biotech Corporation Product Features and Attributes Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026) Table 244. GenScript Biotech Corporation Recent Developments Table 245. Chime Biologics Corporation Information Table 246. Chime Biologics Description and Major Businesses Table 247. Chime Biologics Product Features and Attributes Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026) Table 249. Chime Biologics Recent Developments Table 250. Hangzhou HJB Corporation Information Table 251. Hangzhou HJB Description and Major Businesses Table 252. Hangzhou HJB Product Features and Attributes Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026) Table 254. Hangzhou HJB Recent Developments Table 255. BiBo Pharma Corporation Information Table 256. BiBo Pharma Description and Major Businesses Table 257. BiBo Pharma Product Features and Attributes Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 259. BiBo Pharma Recent Developments Table 260. Technologies, Platforms and Infrastructure Table 261. Distributors List Table 262. Market Trends and Market Evolution Table 263. Market Drivers and Opportunities Table 264. Market Challenges, Risks, and Restraints Table 265. Research Programs/Design for This Report Table 266. Key Data Information from Secondary Sources Table 267. Key Data Information from Primary Sources List of Figures Figure 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Biological Agent Product Picture Figure 3. Biosimilar Drug Product Picture Figure 4. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 5. Drug Substance Manufacturing Product Picture Figure 6. Drug Product Manufacturing Product Picture Figure 7. Integrated Drug Substance and Drug Product Manufacturing Product Picture Figure 8. Others Product Picture Figure 9. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Preclinical and IND-enabling Manufacturing Product Picture Figure 11. Phase I Clinical Manufacturing Product Picture Figure 12. Phase II Clinical Manufacturing Product Picture Figure 13. Phase III Clinical Manufacturing Product Picture Figure 14. Others Product Picture Figure 15. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 16. Oncology Figure 17. Immunology and Autoimmune Diseases Figure 18. Infectious Diseases and Vaccines Figure 19. Metabolic and Endocrine Diseases Figure 20. Neurological Diseases Figure 21. Others Figure 22. Biologics CDMO Report Years Considered Figure 23. Global Biologics CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 24. Global Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 25. Global Biologics CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 26. Global Biologics CDMO Revenue-Based Market Share by Region (2021-2032) Figure 27. Global Biologics CDMO Revenue-Based Market Share Ranking (2025) Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 29. Biological Agent Revenue-Based Market Share by Player in 2025 Figure 30. Biosimilar Drug Revenue-Based Market Share by Player in 2025 Figure 31. Global Biologics CDMO Revenue-Based Market Share by Type (2021-2032) Figure 32. Global Biologics CDMO Revenue-Based Market Share by Manufacturing Service Type (2021-2032) Figure 33. Global Biologics CDMO Revenue-Based Market Share by Development and Commercialization Stage (2021-2032) Figure 34. Global Biologics CDMO Revenue-Based Market Share by Application (2021-2032) Figure 35. North America Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 36. North America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 37. North America Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 38. US Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 39. Canada Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 40. Mexico Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 41. Europe Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 42. Europe Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 43. Europe Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 44. Germany Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 45. France Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 46. U.K. Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 47. Italy Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 48. Russia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 49. Asia-Pacific Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 50. Asia-Pacific Top 8 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 51. Asia-Pacific Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 52. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 53. Japan Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 54. South Korea Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 55. Australia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 56. India Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 57. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 58. Vietnam Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 59. Malaysia Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 60. Philippines Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 61. Singapore Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 62. Central and South America Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 63. Central and South America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 64. Central and South America Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 65. Brazil Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 66. Argentina Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 67. Middle East and Africa Biologics CDMO Revenue YoY (US$ Million), 2021-2032 Figure 68. Middle East and Africa Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025 Figure 69. Middle East and Africa Biologics CDMO Revenue (US$ Million) by Application (2021-2032) Figure 70. GCC Countries Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 71. Israel Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 72. Egypt Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 73. South Africa Biologics CDMO Revenue (US$ Million), 2021-2032 Figure 74. Biologics CDMO Value Chain Mapping Figure 75. Channels of Distribution (Direct Vs Distribution) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート本レポートと同じKEY WORD(biologics)の最新刊レポート
関連レポート(キーワード「バイオ医薬品」)よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|